• Akebia Therapeutics announced U.S. Renal Care halted the VOICE dialysis trial early following an interim analysis showing improved safety outcomes for Vafseo versus ESAs.
• The primary composite outcome improved, driven by fewer hospitalizations; mortality rates showed no meaningful difference between treatment groups.
• Results have not yet been presented; the partners plan to submit the dataset for presentation at an upcoming scientific meeting.
• The readout supports broader clinical positioning for Vafseo in U.S. dialysis centers, where ESAs remain standard anemia therapy.
• Vafseo, an oral therapy launched in the U.S. in January 2025, is approved for once-daily dosing, while VOICE tested three-times-weekly dosing during hemodialysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754668) on June 30, 2026, and is solely responsible for the information contained therein.